The article reports on the results of the Austrian Breast and Colorectal Cancer Study Group trial-12 (ABCSG-12) which showed that previous improvements in disease-free survival (DFS) associated with zoledronic acid were still in effect at 62 months.Hem/onc Today...
0156 Number needed to treat (NNT) as a drug efficacy measure: Zoledronic acid (ZOL) for early hormone-responsive breast cancer in the ABCSG-12 trial This study aims to identify whether patient-level or provider-level characteristics are most influential on a patient's length of stay in the ...
Background: The ABCSG-12 trial investigated the efficacy of gonadotropin-releasing hormone (GnRH)analogs in combination with tamoxifen or anastrozole ± zoledronic acid (4 mg, q6m for 3 years) in 1,803 premenopausal women with hormone receptor-positive (HR+) breast cancer. After 48 months...
Gnant M, Pfeiler G, Steger G G, et al. Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial[J/OL]. ( 2019-2-19) [2019-2-28]. http://doi:...
Background: The ABCSG-12 trial investigated the efficacy of gonadotropin-releasing hormone (GnRH)analogs in combination with tamoxifen or anastrozole ± zoledronic acid (4 mg, q6m for 3 years) in 1,803 premenopausal women with hormone receptor-positive (HR+) breast cancer. After 48 months of ...
AZURE results may contradict ABCSG-12 results for zoledronic acid useHemOnc Today | 33rdAnnual San Antonio Breast Cancer Symposium SAN ANTONIO — Results of the AZURE trial do not support the use ofadjuvant zoledronic acid for the treatment of early breast cancer, according tofindings presented ...
RESULTS: 292 pts were accrued to the trial between 6/199 and 12/2002 and 288 pts are eligible. Both trial groups were well balanced for tumor size, clinical nodal status, menopausal status, hormone receptor status, HER2-status, and trial center. The results of the primary and the secondary...